H_2受体抑制药的发展 H_2受体抑制药是消化性溃疡治疗中最重要的一类药物。治疗溃疡的用量总结见表1。其中第一个H_2受体抑制药西咪替丁于1976年上市,由于它对H_2受体亲和力低,所以治疗溃疡时的剂量需口服一日800mg,然而该药却开拓了对更有效药物的研究。 3～5年后第二个H_2受体抑制药雷尼替丁问世,它抑制组胺引起的胃酸分泌作用较西咪替丁强4～6倍,因此每日300mg就足以控制溃疡。其后,法莫替丁(Famotidine)于1985年在日本首次上市,接着在其他国家也上市。法莫替丁是目前应用的选择性最强 H 2 Receptor Inhibitors H 2 Receptor Inhibitors are the most important class of drugs in the treatment of peptic ulcer. The amount of ulcer treatment summarized in Table 1. One of the first H 2 receptor antagonist cimetidine marketed in 1976, due to its low affinity for H 2 receptor, so the dose of ulcer treatment should be taken orally 800mg a day, but the drug has opened up more effective drug the study. 3 to 5 years after the second H 2 receptor inhibitor Ranitidine came out, it inhibits histamine-induced gastric acid secretion stronger than cimetidine 4 to 6 times, so 300 mg daily enough to control ulcers. Later, Famotidine first went public in Japan in 1985 and then went public in other countries. Famotidine is currently the most selective application